Natural compound Oblongifolin C confers gemcitabine resistance in pancreatic cancer by downregulating Src/MAPK/ERK pathways

Natural compound Oblongifolin C confers gemcitabine resistance in pancreatic cancer by downregulating Src/MAPK/ERK pathwaysNatural compound Oblongifolin C confers gemcitabine resistance in pancreatic cancer by downregulating Src/MAPK/ERK pathways, Published online: 10 May 2018; doi:10.1038/s41419-018-0574-1Natural compound Oblongifolin C confers gemcitabine resistance in pancreatic cancer by downregulating Src/MAPK/ERK pathways

http://feeds.nature.com/~r/cddis/rss/current/~3/ifZq4-za4ng/s41419-018-0574-1

Source: Cell death and disease - May 10, 2018 Category: Internal Medicine Authors: Yang Li Zhichao Xi Xiaoqiong Chen Shuangfan Cai Chen Liang Zhen Wang Yingyi Li Hongsheng Tan Yuanzhi Lao Hongxi Xu Source Type: research

More News: Cancer | Cancer & Oncology | Internal Medicine | Pancreas | Pancreatic Cancer